Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02142, USA; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02142, USA.
Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02142, USA; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02142, USA; Harvard-Massachusetts Institute of Technology, Division of Health Science and Technology, Massachusetts Institute of Technology, Cambridge, MA 02142, USA; Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA 02142, USA.
Cell. 2023 Apr 13;186(8):1535-1540. doi: 10.1016/j.cell.2023.02.031.
Decades of oncologic clinical use have demonstrated that cancer immunotherapy provides unprecedented therapeutic benefits. Tragically, only a minority of patients respond to existing immunotherapies. RNA lipid nanoparticles have recently emerged as modular tools for immune stimulation. Here, we discuss advancements in RNA-based cancer immunotherapies and opportunities for improvement.
几十年来的肿瘤临床应用表明,癌症免疫疗法提供了前所未有的治疗益处。可悲的是,只有少数患者对现有的免疫疗法有反应。RNA 脂质纳米颗粒最近作为免疫刺激的模块化工具出现。在这里,我们讨论了基于 RNA 的癌症免疫疗法的进展和改进的机会。